ESMO MAP 2022 | The advantages of patient-derived using xenograft models for preclinical oncology research

Robert Hynds, PhD, UCL, London, UK, discusses the advantaged of patient derived xenograft (PDX) models for preclinical oncology research over other preclinical methods, such as cell lines. PDX models are more likely to be representative of patient tumors and are therefore more reliable model for preclinical research. Additionally, PDX models offer an in vivo environment that can recapitulate aspects of the tumor microenvironment. This interview took place at the Molecular Analysis for Precision oncology (MAP) Congress 2022 in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.